Reducing minimal residual disease with blinatumomab prior to HCT for pediatric patients with acute lymphoblastic leukemia

Blood Adv. 2019 Jul 9;3(13):1926-1929. doi: 10.1182/bloodadvances.2018025726.

¹ Department of Pediatrics, University of Colorado School of Medicine and The Children's Hospital of Colorado, Aurora, CO.
² Children's Minnesota, Minneapolis, MN.
³ Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH.
⁴ Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
⁵ Children's Hospital Los Angeles, Keck School of Medicine of USC, Los Angeles, CA; and.
⁶ Children's Hospital of Wisconsin, Milwaukee, WI.

Abstract

Children treated with blinatumomab for B-ALL with MRD had few side effects and proceeded to hematopoietic cell transplant without delay.
Blinatumomab given prior to transplant reduces MRD and results in favorable leukemia-free survival, toxicity, and overall survival.